Moving On “SC134-TCB, targeting a supremely SCLC-selective glycolipid, FucGM1, represents an attractive development candidate as an additional T cell–redirecting therapy option for patients ...

It was determined whether overlapping MFS and GBS (MFS/GBS), as well as overlapping BBE and GBS (BBE/GBS), is explained by the combined action of anti-GQ1b IgG and anti-GM1 or anti-GD1a IgG, ...